Skip to content
DIAFIR logo — company profile

DIAFIR

Founded 2011 France France 2 employees Venture round Total: $1.37M Biotechnology, Manufacturing +2

General Information

Company Name DIAFIR
Founded Year 2011
Location France France
Employees 2
Industries Biotechnology, Manufacturing, Medical Devices +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with DIAFIR. To contact DIAFIR, visit diafir.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DIAFIR compare?

A PDF of DIAFIR and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DIAFIR soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DIAFIR

DIAFIR, founded in 2011, is a French innovator at the intersection of Biotechnology, Manufacturing, and Medical Devices. The company specializes in developing rapid, in situ biological analytical tools leveraging proprietary infra-red fiber sensor technology.

These groundbreaking systems have significant applications in POC medical diagnostics, food analysis, and monitoring organic chemical reactions. Notably, DIAFIR's technology can identify chronic liver disease, infections, or tumors in a swift five-minute process, positioning itself as a pivotal player in advancing medical diagnostics efficiency.

Recently, the company secured a substantial €800.00K Venture Round on May 19, 2021, funded by notable investors Go Capital and Happy Capital. This investment underscores the confidence and potential investors see in DIAFIR's innovative contributions to the healthcare sector. Based in France, the company is at the forefront of sensor technology, promising significant impact across its targeted industries.

Business keywords: biological analytical tools, in situ, infra red fiber sensor technology, POC medical diagnostic, food analysis, chemical reaction monitoring, chronic liver disease detection, infection detection, tumor detection, fast analysis, diagnostic technology, medical equipment

Services & Products

In vitro diagnostic device development
Spectroscopic analysis technology
Diagnostic testing for liver diseases
Synovial fluid infection risk assessment

Target Customers

Healthcare providers Medical laboratories Clinicians specializing in liver diseases Veterinary diagnostics

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €800.00K 2
Go Capital, Happy Capital
19 May 2021
Venture Round €270.00K 1
Go Capital
14 Jan 2015
Seed Round €300.00K 1
Go Capital
14 Jun 2012

DIAFIR Alternatives & Competitors

View All Alternatives
DIAFIR vs
Apollon
Apollon Korea South

The wearable that reads your glucose

Seed
40 employees
Biotechnology, Health Care
DIAFIR vs

Molecular diagnosis everywhere, at the right time and for the right price.

Grant
26 employees
Biotechnology, Health Care
DIAFIR vs

Quantifying functional liver capacity

Series C
9 employees
Biotechnology, Medical Devices

FAQ About DIAFIR

DIAFIR developps, manufactures and markets in situ and fast biological analytical tools based upon unique infra red fiber sensor technology. Major applications are POC medical diagnostic, food analysis and organic chemical reaction monitoring. DIAIFR systems allow to detect some chonic liver disea...
DIAFIR was founded in 2011.
DIAFIR is headquartered in France.
DIAFIR operates in Biotechnology, Manufacturing, Medical Devices and Autonomous and Sensor Tech. Its work centres on biological analytical tools, in situ, infra red fiber sensor technology and POC medical diagnostic. Its customers include Healthcare providers, Medical laboratories and Clinicians specializing in liver diseases.
DIAFIR has approximately 2 employees.
DIAFIR has completed 3 funding rounds, raising a total of $1.37M. The latest funding stage is Venture round.
DIAFIR offers: In vitro diagnostic device development, Spectroscopic analysis technology, Diagnostic testing for liver diseases, Synovial fluid infection risk assessment.
Top alternatives and competitors to DIAFIR include Apollon, Genomtec SA, Humedics GmbH, WallabyPhenox, Prestodiag. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DIAFIR and Apollon are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DIAFIR, https://bouncewatch.com/company/diafir, updated 16 September 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout